Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

U.S. Congress · HR8205 · Floor

Progression

Timing in context

Primary sponsor's contributions received (same period)

Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.

What the bill says

HR8205 · U.S. Congress · Floor

Introduced 2026-04-06. Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

View on Congress.gov →

Summary (plain-language)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Sponsors

Text versions

  • Introduced in House — 2026-04-06 — XML
  • Reported in House — 2026-07-09 — XML
  • Engrossed in House — 2026-07-22 — XML

What analysts say

Committee reports

  • H. Rept. 119-733
    Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Off…

    Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available.

    CBO cost estimate from the committee report (public domain).

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2026-07-23Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
2026-07-22Considered as unfinished business.
2026-07-22Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
2026-07-22On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
2026-07-22Motion to reconsider laid on the table Agreed to without objection.
2026-07-20Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
2026-07-20Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
2026-07-20DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
2026-07-20At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
2026-07-09Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
2026-07-09Placed on the Union Calendar, Calendar No. 637.
2026-05-21Committee Consideration and Mark-up Session Held
2026-05-21Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
2026-05-13Subcommittee Consideration and Mark-up Session Held
2026-05-13Forwarded by Subcommittee to Full Committee by Voice Vote.
2026-04-06Introduced in House
2026-04-06Referred to the House Committee on Energy and Commerce.
2026-04-06Referred to the Subcommittee on Health.

← Back to legislation